The Asian Centre for Liver Diseases & Transplantation (ACLDT) was established in 1994. Based in Singapore, it is one of Asia’s foremost Liver Centres with a dedicated Liver Ward and Intensive Care Unit to complement its highly successful Living Donor Liver Transplantation (LDLT) Programme.

ACLDT is led by renowned liver transplant surgeon, Dato’ Dr Tan Kai Chah, who is also the Executive Chairman of the company. He is supported by a multi-disciplinary team of specialised physicians and surgeons.

ACLDT obtained a listing on the Australian Securities Exchange on 29 September 2009 and now trades under the ticker code AJJ.

Core Business

ACLDT, located at Gleneagles Hospital in Singapore, offers a one-stop seamless and comprehensive treatment for patients with liver diseases. With a team of highly trained specialists, state-of-the-art facilities and equipment, the Centre provides optimal care and treatment for adults and children.

ACLDT’s revenue is derived largely from liver transplantation, liver surgery, management of liver diseases through non-surgical methods and related medical services such as liver dialysis, professional medical consultation, imaging and laboratory services.

Over 90% of the Centre’s patients come from South-east Asia, South Asia, Indochina, the Middle East and Russia.

ACLDT is the only commercial private liver centre in the world involved in phase III liver dialysis Extracorporeal Liver Assist Device (ELAD*). In addition, ACLDT also offers two other types of liver dialysis – Molecular Recirculation System (MARS™) and IMPACT – as a bridge to liver transplantation. The utilisation of these three different liver dialysis devices is unique for any liver centre in the world.

Growth Strategies

ALCDT’s growth strategies include:

1) Organic growth of its Singapore operations – through the recruitment of more surgeons. Currently, there is a growing demand for services at ACLDT from the South-east Asia, Indochina and the Middle East regions specifically in the demand for liver transplantation and liver dialysis.

2) Non-Organic growth – through the development of "satellite" liver centres in the region after Vietnam, offering development and management expertise to these centres.

3) Further promote its status as a specialised medical hub for Asia based in Singapore - offering advanced services such as digital database of tissue management, research and development, and entering into formalized relationship with foreign specialists in the field of liver disease including liver cancer.